Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene vs Fulvestrant in ESR1-mutated ER+/HER2- breast cancer
NCT03781063Phase 2Completed
- Sponsor
- Sermonix Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of lasofoxifene in breast cancer, sponsored by Sermonix Pharmaceuticals. Started Sep 2019; status: completed.
02
Drugs
lasofoxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03781063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781063.